{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-046918","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.396683+00:00","generated_at":"2026-06-03T13:17:28.032096+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma boosts CEO and CFO retention bonuses to $200K each","bullets":["Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.","Remaining $165,000 per executive payable on a corporate transaction or clinical development decision approval.","Amendments effective April 22, 2024; original retention letter terms otherwise unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-046918","json":"https://secwatch.observer/filing/0000950170-24-046918.json","markdown":"https://secwatch.observer/filing/0000950170-24-046918.md","text":"https://secwatch.observer/filing/0000950170-24-046918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/0000950170-24-046918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-20240420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:17:28.032096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}